Cargando…
The benefits, costs and feasibility of a low incidence COVID-19 strategy
In the summer of 2021, European governments removed most NPIs after experiencing prolonged second and third waves of the COVID-19 pandemic. Most countries failed to achieve immunization rates high enough to avoid resurgence of the virus. Public health strategies for autumn and winter 2021 have range...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720492/ https://www.ncbi.nlm.nih.gov/pubmed/35005678 http://dx.doi.org/10.1016/j.lanepe.2021.100294 |
_version_ | 1784625140004290560 |
---|---|
author | Czypionka, Thomas Iftekhar, Emil N. Prainsack, Barbara Priesemann, Viola Bauer, Simon Calero Valdez, André Cuschieri, Sarah Glaab, Enrico Grill, Eva Krutzinna, Jenny Lionis, Christos Machado, Helena Martins, Carlos Pavlakis, George N. Perc, Matjaž Petelos, Elena Pickersgill, Martyn Skupin, Alexander Schernhammer, Eva Szczurek, Ewa Tsiodras, Sotirios Willeit, Peter Wilmes, Paul |
author_facet | Czypionka, Thomas Iftekhar, Emil N. Prainsack, Barbara Priesemann, Viola Bauer, Simon Calero Valdez, André Cuschieri, Sarah Glaab, Enrico Grill, Eva Krutzinna, Jenny Lionis, Christos Machado, Helena Martins, Carlos Pavlakis, George N. Perc, Matjaž Petelos, Elena Pickersgill, Martyn Skupin, Alexander Schernhammer, Eva Szczurek, Ewa Tsiodras, Sotirios Willeit, Peter Wilmes, Paul |
author_sort | Czypionka, Thomas |
collection | PubMed |
description | In the summer of 2021, European governments removed most NPIs after experiencing prolonged second and third waves of the COVID-19 pandemic. Most countries failed to achieve immunization rates high enough to avoid resurgence of the virus. Public health strategies for autumn and winter 2021 have ranged from countries aiming at low incidence by re-introducing NPIs to accepting high incidence levels. However, such high incidence strategies almost certainly lead to the very consequences that they seek to avoid: restrictions that harm people and economies. At high incidence, the important pandemic containment measure ‘test-trace-isolate-support’ becomes inefficient. At that point, the spread of SARS-CoV-2 and its numerous harmful consequences can likely only be controlled through restrictions. We argue that all European countries need to pursue a low incidence strategy in a coordinated manner. Such an endeavour can only be successful if it is built on open communication and trust. |
format | Online Article Text |
id | pubmed-8720492 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-87204922022-01-03 The benefits, costs and feasibility of a low incidence COVID-19 strategy Czypionka, Thomas Iftekhar, Emil N. Prainsack, Barbara Priesemann, Viola Bauer, Simon Calero Valdez, André Cuschieri, Sarah Glaab, Enrico Grill, Eva Krutzinna, Jenny Lionis, Christos Machado, Helena Martins, Carlos Pavlakis, George N. Perc, Matjaž Petelos, Elena Pickersgill, Martyn Skupin, Alexander Schernhammer, Eva Szczurek, Ewa Tsiodras, Sotirios Willeit, Peter Wilmes, Paul Lancet Reg Health Eur Health Policy In the summer of 2021, European governments removed most NPIs after experiencing prolonged second and third waves of the COVID-19 pandemic. Most countries failed to achieve immunization rates high enough to avoid resurgence of the virus. Public health strategies for autumn and winter 2021 have ranged from countries aiming at low incidence by re-introducing NPIs to accepting high incidence levels. However, such high incidence strategies almost certainly lead to the very consequences that they seek to avoid: restrictions that harm people and economies. At high incidence, the important pandemic containment measure ‘test-trace-isolate-support’ becomes inefficient. At that point, the spread of SARS-CoV-2 and its numerous harmful consequences can likely only be controlled through restrictions. We argue that all European countries need to pursue a low incidence strategy in a coordinated manner. Such an endeavour can only be successful if it is built on open communication and trust. Elsevier 2022-01-02 /pmc/articles/PMC8720492/ /pubmed/35005678 http://dx.doi.org/10.1016/j.lanepe.2021.100294 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Health Policy Czypionka, Thomas Iftekhar, Emil N. Prainsack, Barbara Priesemann, Viola Bauer, Simon Calero Valdez, André Cuschieri, Sarah Glaab, Enrico Grill, Eva Krutzinna, Jenny Lionis, Christos Machado, Helena Martins, Carlos Pavlakis, George N. Perc, Matjaž Petelos, Elena Pickersgill, Martyn Skupin, Alexander Schernhammer, Eva Szczurek, Ewa Tsiodras, Sotirios Willeit, Peter Wilmes, Paul The benefits, costs and feasibility of a low incidence COVID-19 strategy |
title | The benefits, costs and feasibility of a low incidence COVID-19 strategy |
title_full | The benefits, costs and feasibility of a low incidence COVID-19 strategy |
title_fullStr | The benefits, costs and feasibility of a low incidence COVID-19 strategy |
title_full_unstemmed | The benefits, costs and feasibility of a low incidence COVID-19 strategy |
title_short | The benefits, costs and feasibility of a low incidence COVID-19 strategy |
title_sort | benefits, costs and feasibility of a low incidence covid-19 strategy |
topic | Health Policy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720492/ https://www.ncbi.nlm.nih.gov/pubmed/35005678 http://dx.doi.org/10.1016/j.lanepe.2021.100294 |
work_keys_str_mv | AT czypionkathomas thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT iftekharemiln thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT prainsackbarbara thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT priesemannviola thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT bauersimon thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT calerovaldezandre thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT cuschierisarah thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT glaabenrico thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT grilleva thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT krutzinnajenny thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT lionischristos thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT machadohelena thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT martinscarlos thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT pavlakisgeorgen thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT percmatjaz thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT peteloselena thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT pickersgillmartyn thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT skupinalexander thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT schernhammereva thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT szczurekewa thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT tsiodrassotirios thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT willeitpeter thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT wilmespaul thebenefitscostsandfeasibilityofalowincidencecovid19strategy AT czypionkathomas benefitscostsandfeasibilityofalowincidencecovid19strategy AT iftekharemiln benefitscostsandfeasibilityofalowincidencecovid19strategy AT prainsackbarbara benefitscostsandfeasibilityofalowincidencecovid19strategy AT priesemannviola benefitscostsandfeasibilityofalowincidencecovid19strategy AT bauersimon benefitscostsandfeasibilityofalowincidencecovid19strategy AT calerovaldezandre benefitscostsandfeasibilityofalowincidencecovid19strategy AT cuschierisarah benefitscostsandfeasibilityofalowincidencecovid19strategy AT glaabenrico benefitscostsandfeasibilityofalowincidencecovid19strategy AT grilleva benefitscostsandfeasibilityofalowincidencecovid19strategy AT krutzinnajenny benefitscostsandfeasibilityofalowincidencecovid19strategy AT lionischristos benefitscostsandfeasibilityofalowincidencecovid19strategy AT machadohelena benefitscostsandfeasibilityofalowincidencecovid19strategy AT martinscarlos benefitscostsandfeasibilityofalowincidencecovid19strategy AT pavlakisgeorgen benefitscostsandfeasibilityofalowincidencecovid19strategy AT percmatjaz benefitscostsandfeasibilityofalowincidencecovid19strategy AT peteloselena benefitscostsandfeasibilityofalowincidencecovid19strategy AT pickersgillmartyn benefitscostsandfeasibilityofalowincidencecovid19strategy AT skupinalexander benefitscostsandfeasibilityofalowincidencecovid19strategy AT schernhammereva benefitscostsandfeasibilityofalowincidencecovid19strategy AT szczurekewa benefitscostsandfeasibilityofalowincidencecovid19strategy AT tsiodrassotirios benefitscostsandfeasibilityofalowincidencecovid19strategy AT willeitpeter benefitscostsandfeasibilityofalowincidencecovid19strategy AT wilmespaul benefitscostsandfeasibilityofalowincidencecovid19strategy |